Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 4
2015 4
2016 2
2017 5
2018 2
2019 4
2020 4
2021 8
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. Cantini L, et al. Among authors: festino l. J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061. J Natl Cancer Inst. 2023. PMID: 37042716 Free PMC article.
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M, Palmieri G, Cavalcanti E, Caracò C, Ascierto PA. Capone M, et al. Among authors: festino l. J Immunother Cancer. 2018 Jul 16;6(1):74. doi: 10.1186/s40425-018-0383-1. J Immunother Cancer. 2018. PMID: 30012216 Free PMC article.
Immunotherapy Assessment: A New Paradigm for Radiologists.
Granata V, Fusco R, Setola SV, Simonetti I, Picone C, Simeone E, Festino L, Vanella V, Vitale MG, Montanino A, Morabito A, Izzo F, Ascierto PA, Petrillo A. Granata V, et al. Among authors: festino l. Diagnostics (Basel). 2023 Jan 13;13(2):302. doi: 10.3390/diagnostics13020302. Diagnostics (Basel). 2023. PMID: 36673112 Free PMC article. Review.
Epigenetic Regulation in Melanoma: Facts and Hopes.
Giunta EF, Arrichiello G, Curvietto M, Pappalardo A, Bosso D, Rosanova M, Diana A, Giordano P, Petrillo A, Federico P, Fabozzi T, Parola S, Riccio V, Mucci B, Vanella V, Festino L, Daniele B, Ascierto PA, Ottaviano M, On Behalf Of Scito Youth. Giunta EF, et al. Among authors: festino l. Cells. 2021 Aug 11;10(8):2048. doi: 10.3390/cells10082048. Cells. 2021. PMID: 34440824 Free PMC article. Review.
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study.
Bai X, Shaheen A, Grieco C, d'Arienzo PD, Mina F, Czapla JA, Lawless AR, Bongiovanni E, Santaniello U, Zappi H, Dulak D, Williamson A, Lee R, Gupta A, Li C, Si L, Ubaldi M, Yamazaki N, Ogata D, Johnson R, Park BC, Jung S, Madonna G, Hochherz J, Umeda Y, Nakamura Y, Gebhardt C, Festino L, Capone M, Ascierto PA, Johnson DB, Lo SN, Long GV, Menzies AM, Namikawa K, Mandala M, Guo J, Lorigan P, Najjar YG, Haydon A, Quaglino P, Boland GM, Sullivan RJ, Furness AJS, Plummer R, Flaherty KT. Bai X, et al. Among authors: festino l. EClinicalMedicine. 2023 Oct 31;65:102290. doi: 10.1016/j.eclinm.2023.102290. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37965433 Free PMC article.
PD-L1 inhibitors in the pipeline: Promise and progress.
Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA. Vanella V, et al. Among authors: festino l. Oncoimmunology. 2017 Sep 21;7(1):e1365209. doi: 10.1080/2162402X.2017.1365209. eCollection 2017. Oncoimmunology. 2017. PMID: 29296516 Free PMC article. Review.
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.
Vanella V, Festino L, Vitale MG, Alfano B, Ascierto PA. Vanella V, et al. Among authors: festino l. Expert Opin Emerg Drugs. 2021 Jun;26(2):79-92. doi: 10.1080/14728214.2021.1901884. Epub 2021 Mar 19. Expert Opin Emerg Drugs. 2021. PMID: 33686894 Review.
Nivolumab for the treatment of small cell lung cancer.
Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Curvietto M, Ascierto PA. Simeone E, et al. Among authors: festino l. Expert Rev Respir Med. 2020 Jan;14(1):5-13. doi: 10.1080/17476348.2020.1681977. Epub 2019 Oct 29. Expert Rev Respir Med. 2020. PMID: 31622114 Review.
43 results